

          -  Patients who are hospitalized for inpatient treatment or currently being evaluated for
             potential hospitalization at the time of initiation of informed consent

               1. Patients with a known allergy to Peginterferon Lambda-1a or any component thereof

               2. Room air oxygen saturation of <92%

               3. Participation in a clinical trial with or use of any investigational agent within
                  30 days before screening, or treatment with interferons (IFN) or immunomodulators
                  within 12 months before screening

               4. Previous use of Peginterferon Lambda-1a

               5. History or evidence of any intolerance or hypersensitivity to IFNs or other
                  substances contained in the study medication.

               6. Female patients who are pregnant or breastfeeding. Male patients must confirm
                  that their female sexual partners are not pregnant.

               7. Current or previous history of decompensated liver disease (Child-Pugh Class B or
                  C) or hepatocellular carcinoma

               8. Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)

               9. Significant abnormal laboratory test results at screening.

              10. Significant concurrent illnesses and other comorbidities that may require
                  intervention during the study

              11. Concurrent use of any of the following medications:

                    1. Therapy with an immunomodulatory agent

                    2. Current use of heparin or Coumadin

                    3. Received blood products within 30 days before study randomization

                    4. Use of hematologic growth factors within 30 days before study randomization

                    5. Systemic antibiotics, antifungals, or antivirals for treatment of active
                       infection within 14 days before study randomization

                    6. Any prescription or herbal product that is not approved by the investigator

                    7. Long-term treatment (> 2 weeks) with agents that have a high risk for
                       nephrotoxicity or hepatotoxicity unless it is approved by the medical
                       monitor

                    8. Receipt of systemic immunosuppressive therapy within 3 months before
                       screening
      